Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Atossa Therapeutics stock

ATOS
US04962H5063
A2JJ99

Price

1.46
Today +/-
-0.05
Today %
-4.03 %
P

Atossa Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Atossa Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Atossa Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Atossa Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Atossa Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Atossa Therapeutics Stock Price History

DateAtossa Therapeutics Price
10/1/20241.46 undefined
9/30/20241.52 undefined
9/27/20241.51 undefined
9/26/20241.39 undefined
9/25/20241.39 undefined
9/24/20241.40 undefined
9/23/20241.41 undefined
9/20/20241.46 undefined
9/19/20241.46 undefined
9/18/20241.42 undefined
9/17/20241.45 undefined
9/16/20241.51 undefined
9/13/20241.52 undefined
9/12/20241.50 undefined
9/11/20241.52 undefined
9/10/20241.46 undefined
9/9/20241.36 undefined
9/6/20241.33 undefined
9/5/20241.36 undefined
9/4/20241.36 undefined
9/3/20241.34 undefined

Atossa Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Atossa Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Atossa Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Atossa Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Atossa Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Atossa Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Atossa Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Atossa Therapeutics’s growth potential.

Atossa Therapeutics Revenue, EBIT and net profit per share

DateAtossa Therapeutics RevenueAtossa Therapeutics EBITAtossa Therapeutics Net Income
2029e558.08 M undefined0 undefined297.18 M undefined
2028e347.86 M undefined205.83 M undefined183.43 M undefined
2027e123.7 M undefined38.65 M undefined52.17 M undefined
2026e55.55 M undefined-2.42 M undefined-30.14 M undefined
2025e0 undefined-36.85 M undefined-35.28 M undefined
2024e0 undefined-32.98 M undefined-27.58 M undefined
20230 undefined-31.38 M undefined-30.09 M undefined
20220 undefined-27.69 M undefined-26.96 M undefined
20210 undefined-20.52 M undefined-20.61 M undefined
20200 undefined-14.61 M undefined-22.33 M undefined
20190 undefined-17.27 M undefined-17.24 M undefined
20180 undefined-11.43 M undefined-22.88 M undefined
20170 undefined-7.19 M undefined-10.69 M undefined
20160 undefined-7.25 M undefined-6.37 M undefined
20150 undefined-12.76 M undefined-15.76 M undefined
201440,000 undefined-9.82 M undefined-14.66 M undefined
2013630,000 undefined-10.47 M undefined-10.78 M undefined
2012480,000 undefined-5.04 M undefined-5.08 M undefined
20110 undefined-3.34 M undefined-3.44 M undefined
20100 undefined-1.08 M undefined-1.09 M undefined
20090 undefined-120,000 undefined-120,000 undefined

Atossa Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000000000000000055123347558
------------------123.64182.1160.81
---------------------
000000000000000000000
0-1-3-5-10-9-12-7-7-11-17-14-20-27-31-32-36-2382050
------------------3.6430.8959.08-
0-1-3-5-10-14-15-6-10-22-17-22-20-26-30-27-35-3052183297
--200.0066.67100.0040.007.14-60.0066.67120.00-22.7329.41-9.0930.0015.38-10.0029.63-14.29-273.33251.9262.30
0.020.030.050.070.090.130.160.250.974.168.511.31116.95126.62126.08000000
---------------------
Details

Keystats

ⓘ

Revenue and Growth

The Atossa Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Atossa Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200920102011201220132014201520162017201820192020202120222023
                             
0.101.91.76.38.53.737.210.412.639.6136.4110.988.46
0001001000000000000
000000000000000
000000000000000
0010.10.30.80.60.30.40.612.63.86.53.76
0.102.91.96.79.34.33.37.61113.642.2140.2117.492.22
0010020010010020010001001000000
00000000000004.71.71
000000000000000
0004.64.41.91.70.60.10.10.10000
000000000000000
00000.70.40.10.20.200000.62.32
000.14.85.22.420.90.30.20.2005.34.03
0.1036.711.911.76.34.27.911.213.842.2140.2122.796.25
                             
00000000.10.53.52.39.223.423.422.79
0.10.46.214.931.144.654.660.371.982.2104.9129.9244250.8255.99
-0.1-1.2-4.7-9.7-20.5-35.2-50.9-57.3-65.4-76.8-94.1-111.9-129.2-156.2-186.29
000000000000000
000000000000000
0-0.81.55.210.69.43.73.178.913.127.2138.211892.49
000.10.10.20.50.80.30.30.40.31.61.730.81
00.70.41.60.91.21.60.80.91.111.11.42.62.63
00000.30.50.1001.4013001.8
02001,000000000000000
000000000000000
00.91.51.71.42.22.51.11.22.91.315.73.15.65.24
000000000000000
000000000000000
000000000000000
000000000000000
00.91.51.71.42.22.51.11.22.91.315.73.15.65.24
00.136.91211.66.24.28.211.814.442.9141.3123.697.73
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Atossa Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Atossa Therapeutics's financial health and stability.

Assets

Atossa Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Atossa Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Atossa Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Atossa Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20092010201120122013201420152016201720182019202020212022
0-1-3-5-10-14-15-6-8-11-17-17-20-26
00000000000000
00000000000000
0000-100-1000000
00003322241791013
00000000000000
00000000000000
00-3-3-8-10-13-5-6-8-9-11-16-20
00000000000000
0000000000000-4
0000000000000-4
00000000000000
000-10000000000
0053131394101211381130
0053131394101211381130
00-1,0001,0000000000000
00000000000000
001042-404322696-25
-0.08-0.36-3.63-4.03-9.32-10.9-14.08-5.38-6.59-9.07-9.14-11.58-16.48-20.79
00000000000000

Atossa Therapeutics stock margins

The Atossa Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Atossa Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Atossa Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Atossa Therapeutics's sales revenue. A higher gross margin percentage indicates that the Atossa Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Atossa Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Atossa Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Atossa Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Atossa Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Atossa Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Atossa Therapeutics Margin History

Atossa Therapeutics Gross marginAtossa Therapeutics Profit marginAtossa Therapeutics EBIT marginAtossa Therapeutics Profit margin
2029e100 %0 %53.25 %
2028e100 %59.17 %52.73 %
2027e100 %31.24 %42.17 %
2026e100 %-4.36 %-54.27 %
2025e100 %0 %0 %
2024e100 %0 %0 %
2023100 %0 %0 %
2022100 %0 %0 %
2021100 %0 %0 %
2020100 %0 %0 %
2019100 %0 %0 %
2018100 %0 %0 %
2017100 %0 %0 %
2016100 %0 %0 %
2015100 %0 %0 %
2014100 %-24,550 %-36,650 %
201346.03 %-1,661.91 %-1,711.11 %
201293.75 %-1,050 %-1,058.33 %
2011100 %0 %0 %
2010100 %0 %0 %
2009100 %0 %0 %

Atossa Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Atossa Therapeutics earnings per share therefore indicates how much revenue Atossa Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Atossa Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Atossa Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Atossa Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Atossa Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Atossa Therapeutics Revenue, EBIT and net profit per share

DateAtossa Therapeutics Sales per ShareAtossa Therapeutics EBIT per shareAtossa Therapeutics Earnings per Share
2029e4.44 undefined0 undefined2.36 undefined
2028e2.77 undefined0 undefined1.46 undefined
2027e0.98 undefined0 undefined0.41 undefined
2026e0.44 undefined0 undefined-0.24 undefined
2025e0 undefined0 undefined-0.28 undefined
2024e0 undefined0 undefined-0.22 undefined
20230 undefined-0.25 undefined-0.24 undefined
20220 undefined-0.22 undefined-0.21 undefined
20210 undefined-0.18 undefined-0.18 undefined
20200 undefined-1.29 undefined-1.97 undefined
20190 undefined-2.03 undefined-2.03 undefined
20180 undefined-2.75 undefined-5.5 undefined
20170 undefined-7.41 undefined-11.02 undefined
20160 undefined-29 undefined-25.48 undefined
20150 undefined-79.75 undefined-98.5 undefined
20140.31 undefined-75.54 undefined-112.77 undefined
20137 undefined-116.33 undefined-119.78 undefined
20126.86 undefined-72 undefined-72.57 undefined
20110 undefined-66.8 undefined-68.8 undefined
20100 undefined-36 undefined-36.33 undefined
20090 undefined-6 undefined-6 undefined

Atossa Therapeutics business model

Atossa Therapeutics Inc. is a biopharmaceutical company based in Seattle, USA, specializing in the development of therapies for the treatment of breast cancer and other breast diseases. Atossa Therapeutics is one of the most popular companies on Eulerpool.com.

Atossa Therapeutics SWOT Analysis

Strengths

1. Solid Research and Development Phase: Atossa Therapeutics Inc has a strong focus on researching and developing innovative therapeutic products.

2. Expertise in Oncology Field: The company specializes in developing therapeutic solutions for breast cancer and other forms of oncology, leveraging its deep understanding of the field.

3. Strong Intellectual Property: Atossa Therapeutics Inc possesses a robust intellectual property portfolio, providing a competitive advantage and protective barriers.

Weaknesses

1. Limited Market Presence: Atossa Therapeutics Inc currently has limited market share and recognition, resulting in relatively lower brand awareness compared to established competitors.

2. Financial Constraints: The company may face financial challenges due to the high costs associated with research, development, and clinical trials.

3. Dependence on Strategic Partnerships: Atossa Therapeutics Inc relies heavily on collaborations and partnerships to advance its research and market its products.

Opportunities

1. Growing Cancer Therapeutics Market: With an increasing prevalence of cancer worldwide, there is a significant opportunity for Atossa Therapeutics Inc to expand its product offerings and gain market share.

2. Emerging Markets: The company can explore opportunities in untapped markets, especially in developing countries where the demand for advanced cancer treatments is rising.

3. Advances in Technology: As technology continues to evolve, Atossa Therapeutics Inc can leverage advancements in areas such as precision medicine, genomics, and personalized treatments to develop more effective therapies.

Threats

1. Intense Competition: The cancer therapeutics industry is highly competitive, with numerous established players and new entrants. Atossa Therapeutics Inc faces the risk of losing market share to competitors with stronger brand presence and resources.

2. Regulatory Challenges: Regulatory requirements and approval processes can pose significant hurdles for the development and commercialization of new therapies, potentially delaying market entry.

3. Clinical Trial Risks: The success of Atossa Therapeutics Inc's products relies on successful clinical trial outcomes, which are subject to uncertainties and the possibility of adverse events or failure to meet efficacy endpoints.

Atossa Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Atossa Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Atossa Therapeutics shares outstanding

The number of shares was Atossa Therapeutics in 2023 — This indicates how many shares 126.082 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Atossa Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Atossa Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Atossa Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Atossa Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Atossa Therapeutics stock splits

In Atossa Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Atossa Therapeutics.

Atossa Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.06 -0.05  (13.49 %)2024 Q2
3/31/2024-0.07 -0.05  (26.47 %)2024 Q1
12/31/2023-0.06 -0.09  (-55.71 %)2023 Q4
9/30/2023-0.07 -0.05  (29.97 %)2023 Q3
6/30/2023-0.06 -0.08  (-30.72 %)2023 Q2
3/31/2023-0.06 -0.05  (18.3 %)2023 Q1
12/31/2022-0.06 -0.06  (1.96 %)2022 Q4
9/30/2022-0.06 -0.06  (1.96 %)2022 Q3
6/30/2022-0.06 -0.05  (18.3 %)2022 Q2
3/31/2022-0.05 -0.04  (21.57 %)2022 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the Atossa Therapeutics stock

Eulerpool World ESG Rating (EESG©)

49/ 100

🌱 Environment

50

👫 Social

70

🏛️ Governance

27

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Atossa Therapeutics shareholders

%
Name
Stocks
Change
Date
6.17247 % Heights Capital Management, Inc.7,762,5007,762,5003/15/2024
4.51314 % The Vanguard Group, Inc.5,675,724012/31/2023
1.84753 % BlackRock Institutional Trust Company, N.A.2,323,450012/31/2023
1.76988 % Laurion Capital Management LP2,225,800012/31/2023
1.02121 % Renaissance Technologies LLC1,284,27041,90012/31/2023
0.88655 % Geode Capital Management, L.L.C.1,114,92412,34812/31/2023
0.35709 % GSA Capital Partners LLP449,082101,69012/31/2023
0.34691 % State Street Global Advisors (US)436,271012/31/2023
0.28045 % BMO Capital Markets (US)352,700352,70012/31/2023
0.27132 % BlackRock Financial Management, Inc.341,211-90,08012/31/2023
1
2
3
4
5
...
10

Atossa Therapeutics Executives and Management Board

Dr. Steven Quay72
Atossa Therapeutics Chairman of the Board, President, Chief Executive Officer (since 2009)
Compensation 3.16 M
Mr. Richard Steinhart66
Atossa Therapeutics Independent Director
Compensation 119,370
Dr. Stephen Galli76
Atossa Therapeutics Independent Director
Compensation 114,370
Mr. H. Lawrence Remmel71
Atossa Therapeutics Independent Director
Compensation 114,370
Dr. Shu-Chih Chen61
Atossa Therapeutics Director (since 2009)
Compensation 89,370
1
2

Most common questions regarding Atossa Therapeutics

What values and corporate philosophy does Atossa Therapeutics represent?

Atossa Therapeutics Inc represents a commitment to delivering innovative solutions in the field of oncology and developing therapies for breast cancer and other related conditions. The company aims to advance medical science by conducting extensive research and clinical trials to address unmet medical needs. Atossa Therapeutics Inc prioritizes patient well-being, scientific excellence, and the pursuit of novel therapeutic approaches. With a focus on improving patient outcomes, the company emphasizes collaboration, transparency, and integrity in its operations. As a leading biopharmaceutical company, Atossa Therapeutics Inc consistently strives to make significant contributions to the field of oncology.

In which countries and regions is Atossa Therapeutics primarily present?

Atossa Therapeutics Inc primarily operates in the United States.

What significant milestones has the company Atossa Therapeutics achieved?

Atossa Therapeutics Inc, a leading biopharmaceutical company, has achieved several significant milestones. Firstly, they successfully developed Endoxifen, a potential treatment for breast cancer patients. Additionally, Atossa Therapeutics obtained a patent for a proprietary oral form of Endoxifen, providing them with a competitive advantage in the market. Furthermore, the company received FDA clearance to initiate Phase 2 clinical trials for the oral Endoxifen in breast cancer patients. Atossa Therapeutics also made noteworthy progress in the field of COVID-19 with the launch of a clinical study for a nasal spray known as AT-301. These milestones demonstrate the company's commitment to advancing innovative treatments and improving patient outcomes.

What is the history and background of the company Atossa Therapeutics?

Atossa Therapeutics Inc is a biopharmaceutical company specializing in the development of innovative therapeutics for the treatment of breast cancer and other related conditions. Founded in 2009, Atossa Therapeutics has consistently aimed to improve the lives of patients through advanced medical solutions. The company has focused on developing proprietary drugs and medical devices designed to address the unmet needs in breast health and oncology. With a team of dedicated researchers and industry experts, Atossa Therapeutics Inc continues to make significant strides in the field of breast cancer treatment, offering hope for patients worldwide.

Who are the main competitors of Atossa Therapeutics in the market?

The main competitors of Atossa Therapeutics Inc in the market include Genomic Health Inc, Exact Sciences Corporation, and Guardant Health Inc.

In which industries is Atossa Therapeutics primarily active?

Atossa Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Atossa Therapeutics?

The business model of Atossa Therapeutics Inc is focused on developing innovative therapeutics and diagnostics for breast cancer. The company specializes in the development of novel drugs to treat breast cancer and other breast conditions. Atossa Therapeutics Inc also offers services related to the collection, storage, and analysis of biological samples, aiding in the early detection and prevention of breast cancer. By leveraging its expertise in pharmaceutical research and diagnostic capabilities, the company aims to improve the lives of patients affected by breast cancer and contribute to advancements in the field of oncology.

What is the P/E ratio of Atossa Therapeutics 2024?

The Atossa Therapeutics P/E ratio is -6.67.

What is the P/S ratio of Atossa Therapeutics 2024?

The Atossa Therapeutics P/S ratio is 0.

What is the AlleAktien quality score of Atossa Therapeutics?

The AlleAktien quality score for Atossa Therapeutics is 4/10.

What is the revenue of Atossa Therapeutics 2024?

The revenue cannot currently be calculated for Atossa Therapeutics.

How high is the profit of Atossa Therapeutics 2024?

The expected Atossa Therapeutics profit is -27.58 M USD.

What is the business model of Atossa Therapeutics

Atossa Therapeutics Inc. is an American biopharmaceutical company that focuses on developing innovative therapies for the treatment of breast cancer and other breast disorders. The company offers a wide range of products and services based on different technologies and methods to ensure precise and effective treatment. They specialize in developing drugs and medical devices for the prevention and treatment of breast cancer. They also conduct research in the field of gene therapy and manufacture medical devices for breast cancer screening and diagnosis. Atossa Therapeutics collaborates with research institutions and universities to constantly develop and market new products and services. Their business model is based on the belief that the development of innovative therapies and close collaboration with research institutions and doctors are the best ways to develop effective treatment methods and win the fight against breast cancer.

What is the Atossa Therapeutics dividend?

Atossa Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Atossa Therapeutics pay dividends?

The dividend cannot currently be calculated for Atossa Therapeutics or the company does not pay out a dividend.

What is the Atossa Therapeutics ISIN?

The ISIN of Atossa Therapeutics is US04962H5063.

What is the Atossa Therapeutics WKN?

The WKN of Atossa Therapeutics is A2JJ99.

What is the Atossa Therapeutics ticker?

The ticker of Atossa Therapeutics is ATOS.

How much dividend does Atossa Therapeutics pay?

Over the past 12 months, Atossa Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Atossa Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Atossa Therapeutics?

The current dividend yield of Atossa Therapeutics is .

When does Atossa Therapeutics pay dividends?

Atossa Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Atossa Therapeutics?

Atossa Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Atossa Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Atossa Therapeutics located?

Atossa Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Atossa Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Atossa Therapeutics from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Atossa Therapeutics pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Atossa Therapeutics in the year 2023?

In the year 2023, Atossa Therapeutics distributed 0 USD as dividends.

In which currency does Atossa Therapeutics pay out the dividend?

The dividends of Atossa Therapeutics are distributed in USD.

All fundamentals about Atossa Therapeutics

Our stock analysis for Atossa Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Atossa Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.